Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2016

View Archived Issues

Vyriad enters global license agreement with Stinginn

Eisai reviews accomplishments of first quarter of fiscal 2016

Merck & Co. patents BACE1 and -2 inhibitors

Sumitomo Dainippon Pharma discloses Nav1.7 channel blockers

Millennium Pharmaceuticals describes Nampt inhibitors

Scripps Research Institute develops MCT1 and/or MCT4 inhibitors

MyoKardia presents cardiac myosin activators

MMRF and University of Michigan collaborate on a new molecular profiling initiative

Autologous BMC is safe and effective in treating patients with atrophic non-unions

FDA accepts Merck & Co.'s MK-1293 NDA for review

Mylan completes public offer settlement with Meda

CheckMate 026 phase III study of Opdivo does not meet primary endpoint

ZSYM73 affibody in a mouse model of AD

Shire reports recent developments of second quarter 2016

UT Southwestern receives funding from NCI to target rising rates of kidney cancer

Hematogenix announces launch of Ventana PD-L1 (SP142) and (SP263) assays

FDA approves Merck & Co.'s Keytruda for patients with recurrent or metastatic HNSCC

Lantern Pharma to evaluate BioNumerik's Tavocept

FDA grants orphan drug designation to vedolizumab

Boehringer Ingelheim begins phase II trial of BI-425809 in patients with schizophrenia

Phase II trial of volixibat in patients with NASH recruiting patients

Tolerogenic nanoparticles improve biologic drug efficacy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 7, 2025.
House passes H.R. 1, restoring R&D tax cuts
BioWorld MedTech
The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
With surface mimicry, molecular glues shed hairpin need
BioWorld Science
Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
Exercise-mimicking compound offers alternative to GLP-1 therapies
BioWorld
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...